ECCO 2022

Combination trials open a new door in IBD treatment

Combined endpoints as new therapy goals

Is the continuation of combination therapy the key to…

The potential of histology in Crohn´s disease and how…

Microbiota manipulation: Still a lot to learn

SPARE study in ECCO 2022

FMT in UC - still far away from the success story

When to withdraw therapy in crohn's disease?

Ustekinumab for fistulizing disease

Proactive TDM

Combination with different classes of drugs in moderate…

The interleukin-17 conundrum

Will we improve the management of IBD by combining…

The first combination therapy trial

A new opportunity for proactive TDM disease control

How to deescalate treatment in CD?

Combination of biologics

Is the speedity of the steroid tapering important…

Combination of biologics - finally arrived in IBD!?

A negative control trial for FMT in UC

Filgotinib for fistulizing disease

FMT is not a promising option for UC patients

Withdrawal of infliximab or anti-metabolite therapy in…

Is stopping of therapy an option in CD?

Proactive TDM or SOC for monitoring infliximab…

Una nuova opportunità per i TDM nel controllo proattivo…

מחקר SPARE ב ECCO 2022

Combinazione di biologici

Il primo trial di terapia biologica di combinazione

Ist der Therapiestopp eine Option in CD?

FMT ist kein vielversprechender Ansatz für UC-Patienten

Wann Beendigung von Infliximab oder Immunmodulatoren…

Kombination von Biologika - endlich bei IBD…

Προληπτική μέτρηση των θεραπευτικών επιπέδων του…

Allons nous améliorer la prise en charge des MICI en…

Επηρεάζει η ταχύτητα διακοπής των κορτικοστεροειδών την…

Das Interleukin-17 Rätsel

Un essai négatif sur la transplantation de microbiote…

FMT w colitis ulcerosa - wciąż daleko od sukcesu

Can we translate rheumatoid arthritis to ulcerative…

COVID-19: still a moving target!

Inflammatory bowel disease and cancer risk

Which IBD patients have a higher risk of safety…

A touch of the near future in IBD treatment

The heart is apparently safe with continuous Ozanimod…

Uno sguardo al prossimo futuro nel trattamento delle…

Muttermilch beeinflusst das IBD-Risiko

Vedolizumab: promising data for pouchitis and IBD in…

Efficacy update on JAKis

Fistulizing Crohn‘s disease - new treatment options…

The race is on IL-23 – exciting data for CD and UC

Upadacitinib - will it be the game changer in UC?

JAK inhibition

Vedolizumab is effective in chronic pouchitis after…

Guselkumab as maintenace treatment in Crohn's Disease

New opportunity in pouchitis treatment

Great news on pouchitis treatment - vedolizumab…

Selective IL-23 blockade

Anti-IL-23 - a turning point?

Vedolizumab in chronic pouchitis - a new chapter in…

Anti-IL-23 - eine Zeitenwende?

JAK-Inhibition

Selektive IL-23 Blockade

Guselkumab come terapia di mantenimento

Wedolizumab w pouchitis - początek nowego rozdziału w…

Una nuova opportunità nel trattamemto della pouchite

Nuevos caminos en el tratamiento

New therapeutic goals in UC

Patient relevant outcomes also show efficacy of…

Natural history of anal ulcerations in pediatric-onset…

New therapy goals: urgency and disease clearance

Histological findings in mirikizumab treatment

New goals for IBD

Histoire naturelle de la maladie de Crohn ano-périnéale…

Nuevas objetivos en las EII

Disease Control ist möglich!

COVID-19 in patients with IBD stratified acc. to…

Skuteczność szczepień przeciw COVID-19 w IBD - nowe…

Ultrasound as a predictor of treatment response

Ultraschall als Prädiktor des Therapieansprechens

Spanish women leading contribution to ECCO 2022

ECCO Richtlijnen zwangerschap